A blind patient partially recovers sight after optogenetic therapy
An international research team led by Prof José-Alain Sahel, Prof Botond Roska, and associating two beneficiaries of the enTRAIN Vision project : the Institut de la Vision (Sorbonne University / Inserm / CNRS) and Streetlab as well as the XV-XX ophthalmology hospital, the University of Pittsburgh , the Basel Institute of Molecular and Clinical Ophthalmology (IOB), the company GenSight Biologics, have shown that optogenetic therapy can partially restore vision in a blind patient with advanced retinopathy pigmentosa.
The results were published in the journal “Nature Medicine” on May 24, 2021. You can read the publication below.